Windtree Therapeutics up as heart disease drug meets main goal in mid-stage study

Windtree Therapeutics

29/09/2022 10:53

** Windtree Therapeutics Inc's shares  WINT.O  surge 53.7%
to $0.5 - biggest pct gainer across US stock exchanges premarket
    ** WINT says its experimental drug to treat patients with
early cardiogenic shock met its main goal of significantly
improving blood pressure compared to the control group at 6
hours in mid-stage study
    ** Cardiogenic shock is a life-threatening condition in
which your heart suddenly can't pump enough blood to meet your
body's needs
    ** The drug also met several other secondary goals 
    ** Up to Wednesday's close, stock had fallen ~80% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))